MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Change in Cash
-$28,313K
Free Cash flow
-$29,917K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Stock-based compensation expense
Proceeds from the exercise of st...
Accretion of debt discount and n...
Others
Negative Cash Flow Breakdown
Operating lease liability
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net loss
-36,650
-33,441
-32,834
-35,256
Depreciation and amortization
523
537
564
583
Accretion of debt discount and non-cash interest expense
1,291
732
642
638
Stock-based compensation expense
3,104
2,653
2,743
3,175
Non-cash lease expense
-
-
1,803
-
Non-cash gain on transaction with acquirer
-
-
0
-
Non-cash lease expense
497
-851
-
456
Loss on disposal of fixed assets
-14
-
-9
-3
Non-cash gain on transaction with acquirer
-
-
-
0
Accounts receivable
0
0
46
-127
Other receivables
-54
9
-706
-3
Receivables from related parties
0
0
0
0
Prepaid expenses and other current assets
-371
1,063
-423
-25
Other non-current assets
0
0
0
22
Accounts payable
1,011
2,818
-829
-1,519
Accrued expenses
431
-10,187
-1,434
-1,515
Operating lease liability
-563
-549
-535
-522
Net cash used in operating activities
-29,917
-38,026
-30,122
-33,824
Purchase of property and equipment
0
0
0
10
Proceeds from the sale of property and equipment
-
-
0
3
Net cash used in investing activities
0
0
0
-7
Proceeds from the issuance of debt
0
74,992
0
0
Payment of third-party fees associated with debt
-
-
125
-
Payment of fees associated with debt
0
-125
-
0
Proceeds from the exercise of stock options
1,604
471
1,254
352
Net cash provided by financing activities
1,604
75,463
1,254
352
Net increase in cash and cash equivalents
-28,313
37,437
-28,868
-33,479
Cash and cash equivalents at beginning of period
161,657
124,220
153,088
152,596
Cash and cash equivalents at end of period
133,344
161,657
124,220
153,088
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Proceeds from the
exercise of stock options
$1,604K
Net cash provided by
financing activities
$1,604K
(-98.39%↓ Y/Y)
Net increase in cash
and cash...
-$28,313K
(-183.34%↓ Y/Y)
Canceled cashflow
$1,604K
Stock-based compensation
expense
$3,104K
(-40.54%↓ Y/Y)
Accretion of debt discount
and non-cash...
$1,291K
(11.39%↑ Y/Y)
Accounts payable
$1,011K
(206.09%↑ Y/Y)
Depreciation and
amortization
$523K
(-60.85%↓ Y/Y)
Non-cash lease expense
$497K
(-43.39%↓ Y/Y)
Accrued expenses
$431K
(130.52%↑ Y/Y)
Prepaid expenses and
other current assets
-$371K
(61.03%↑ Y/Y)
Other receivables
-$54K
(-107.84%↓ Y/Y)
Loss on disposal of
fixed assets
-$14K
Net cash used in
operating activities
-$29,917K
(54.57%↑ Y/Y)
Canceled cashflow
$7,296K
Net loss
-$36,650K
(49.07%↑ Y/Y)
Operating lease liability
-$563K
(-4.65%↓ Y/Y)
Buy us a coffee
Inhibrx Biosciences, Inc. (INBX)
Inhibrx Biosciences, Inc. (INBX)